1. HOME
  2. About Otsuka
  3. Timeline of Otsuka's History 2014～Present
About Otsuka

Timeline of Otsuka's History
2014～Present

1964～1973
1974～1983
1984～1993
1994～2003
2004～2013
2014～Present
  • CorpCorporate
  • PhPharmaceutical business
  • NCNutraceutical business

2014

Ph
Otsuka Australia Pharmaceutical Pty Ltd. established

Otsuka Pharmaceutical opens its first office in Australia, furthering the company's aim of bringing innovative new treatments to patients in Oceania.

Samsca introduced in Japan for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Vasopressin V2-receptor antagonist

DELTYBA launched in Europe and Japan

Treatment for multidrug-resistant tuberculosis (MDR-TB)

NC
EQUELLE launched

2015

Ph
REXULTI launched in the U.S.

Adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia.
(Launched in Japan in 2018.)

2016

Corp
Otsuka Joins UN Global Compact (UNGC)*

Otsuka Holdings Co., Ltd. became a signatory to the United Nations Global Compact (UNGC) in order to express its commitment to corporate social responsibility (CSR) and sustainability.

  • *The Global Compact is an encouragement for companies to pursue sustainable growth and be a good member of society.
Ph
ICLUSIG launched in Japan

Drug for chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

NC
Otsuka Pharmaceutical forms joint venture company for functional food and beverages in the Philippines

2017

Ph
Mikeluna combination ophthalmic solution launched in Japan

Drug for glaucoma and ocular hypertension

Otsuka Pharmaceutical established subsidiary in Singapore
NC
BODYMAINTÉ launched

BODYMAINTÉ Jelly, a conditioning food to support athletic performance

Otsuka established a new functional food and beverage affiliate"Otsuka Nutraceutical (Thailand) Ltd." in Thailand
North America-based Daiya joined the Otsuka group

2018

Ph
JYNARQUE approved by U.S. FDA as the first treatment to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)

Vasopressin V2-receptor antagonist

Visterra joined the Otsuka group

Visterra's exceptional antibody platform technology joined up with Otsuka

NC
Otsuka established health beverage subsidiary in Myanmar

2019

Corp
Tokushima Mima Factory completed
Ph
Selincro launched in Japan

Drug to reduce alcohol consumption in alcohol-dependent patients

NC
Otsuka established health beverage subsidiary in Mexico

2020

Ph
Otsuka established subsidiary in Malaysia

2021

Corp
Otsuka group 100th Anniversary
Ph
AJOVY launched in Japan

An anti-CGRP (calcitonin gene-related peptide) monoclonal antibody for preventive treatment of migraine

NC
U.S.-based Uqora joined the Otsuka group
tocoelle launched

2022

Ph
Moizerto launched in Japan

The first topical PDE4 inhibitor approved in Japan for the treatment of atopic dermatitis

SAMTASU launched in Japan

A prodrug of oral tolvaptan

FACEDUO Launched

Virtual reality (VR) training program supervised by medical specialists

Osaka Research Center for Drug Discovery established
NC
Sakuraé Double Action Serum launched

2023

Ph
ABILIFY ASIMTUFII approved by U.S.

Aripiprazole ,two-month, Long-acting Injectable (LAI)

Brexpiprazole approved by U.S. FDA as a treatment for Agitation Associated with Dementia due to Alzheimer's Disease
Mindset Pharma Inc. joined the Otsuka group
NC
Arab Otsuka Nutraceuicals Co., S.A.E established
Entered into the Ministry of the Environment’s First Partnership Agreement to Advance Heat Illness Prevention Measures
U.S.-based Bonafide Health, LLC, joined the Otsuka group

developing and marketing new nature-inspired health products for women.

2024

Ph
Rejoyn™ launched in US

First Major Depression Treatment App in the world

Rexulti approved in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease
Jnana Therapeutics Inc. joined the Otsuka group
Lupkynis launched in Japan

Oral immunosuppressive agent developed for the treatment of LN.

NC
Otsuka Nutraceutical India Private Limited established
The AR-based nutrition education game app, 'Mogumogu Town,' launched
Nutrition Tracking Service "Vivoo" Launched in Japan

U.S. Originated Nutrition Tracking Service

2025

Ph
MIREVO launched in Japan

Neuropsychological testing program

HemeSight launched in Japan

Comprehensive Genomic Profiling Assay for Hematological Malignancies

NEXLETOL launched in Japan

Treatment of hypercholesterolemia and familial hypercholesterolemia.

1964～1973
1974～1983
1984～1993
1994～2003
2004～2013
2014～Present